A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
Solid Tumor
DRUG: AB-106, digoxin
The PK exposure parameters of digoxin, Area under the plasma concentration versus time curve (AUC), 17 days
The PK parameters of digoxin, Peak Plasma Concentration (Cmax), 17 days|The PK parameters of digoxin, Time to drug peak plasma concentration (Tmax), 17 days|The PK parameters of digoxin, Percentage of area under the curve from time of the last quantifiable concentration to infinity to area under the curve to infinity (AUC_extr%), 17 days|The PK parameters of digoxin, Lambda_z, first-order rate constant associated with the terminal portion of the curve (λz), 17 days|The PK parameters of digoxin, Terminal phase elimination half life (t1/2), 17 days|The PK parameters of digoxin, Apparent total clearance (CL/F), Vz/F, 17 days|The PK parameters of digoxin, Apparent volume of distribution (Vz/F), 17 days|Safety assessment, Adverse events (AEs), 35 days
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）